The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
Open accessAbstract
Purpose: To determine the clinical and biologic effects of bevacizumab, an anti–vascular endothelial growth factor (VEGF) monoclonal antibody, in unresectable hepatocellular carcinoma (HCC). Patients and Methods: Adults with organ-confined HCC, Eastern Cooperative Oncology Group performance status of 0 to 2, and compensated liver disease were eligible. Patients received bevacizumab 5 mg/kg (n = 12) or 10 mg/kg (n = 34) every 2 weeks until disease progression or treatment-limiting toxicity. The primary objective was to determine whether bevacizumab improved the 6-month progression-free survival (PFS) rate from 40% to 60%. Secondary end points included determining the effects of bevacizumab on arterial enhancement and on plasma cytokine levels and the capacity of patients' plasma to support angiogenesis via an in vitro assay. Results: The study included 46 patients, of whom six had objective responses (13%; 95% CI, 3% to 23%), and 65% were progression free at 6 months. Median PFS time was 6.9 months (95% CI, 6.5 to 9.1 months); overall survival rate was 53% at 1 year, 28% at 2 years, and 23% at 3 years. Grade 3 to 4 adverse events included hypertension (15%) and thrombosis (6%, including 4% with arterial thrombosis). Grade 3 or higher hemorrhage occurred in 11% of patients, including one fatal variceal bleed. Bevacizumab was associated with significant reductions in tumor enhancement by dynamic contrast-enhanced magnetic resonance imaging and reductions in circulating VEGF-A and stromal-derived factor-1 levels. Functional angiogenic activity was associated with VEGF-A levels in patient plasma. Conclusion: We observed significant clinical and biologic activity for bevacizumab in nonmetastatic HCC and achieved the primary study end point. Serious bleeding complications occurred in 11% of patients. Further evaluation is warranted in carefully selected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update
El-Serag, H. B., Davila, J. A., Petersen, N. J., & McGlynn, K. A. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00009 · Cited by 943
Morgan, B., Thomas, A. L., Drevs, J., Hennig, J., Buchert, M., Jivan, A., Horsfield, M. A., Mross, K., Ball, H. A., Lee, L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.092 · Cited by 652
Expression of vascular endothelial growth factor in human hepatocellular carcinoma
Yamaguchi, R., Yano, H., Iemura, A., Ogasawara, S., Haramaki, M., & Kojiro, M. (1998) · Hepatology · doi:10.1002/hep.510280111 · Cited by 397
Zhu, A. X., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Muzikansky, A., Horgan, K., Sheehan, S., Hale, K. E., Enzinger, P. C., Bhargava, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9130 · Cited by 388
Jubb, A. M., Hurwitz, H. I., Bai, W., Holmgren, E. B., Tobin, P., Guerrero, A. S., Kabbinavar, F., Holden, S. N., Novotny, W. F., Frantz, G. D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5388 · Cited by 387
Angiogenesis and hepatocellular carcinoma
Semela, D., & Dufour, J.-F. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.006 · Cited by 372
Thomas, M. B., Morris, J. S., Chadha, R., Iwasaki, M., Kaur, H., Lin, E., Kaseb, A., Glover, K., Davila, M., & Abbruzzese, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3301 · Cited by 334
Cited by
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Bevacizumab has been evaluated as single agent [336], or in combination with erlotinib [337] or chemotherapy [338].”
BackgroundVogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Cheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743
Genetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00252-7 · Cited by 1,124
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0022 · Cited by 1,003
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
Whittaker, S., Marais, R., & Zhu, A. X. (2010) · Oncogene · doi:10.1038/onc.2010.236 · Cited by 825
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
Lee, M. S., Ryoo, B.-Y., Hsu, C.-H., Numata, K., Stein, S., Verret, W., Hack, S. P., Spahn, J., Liu, B., Abdullah, H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30156-x · Cited by 562
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Llovet, J. M., Peña, C. E. A., Lathia, C. D., Shan, M., Meinhardt, G., & Bruix, J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2175 · Cited by 559
Kaplan, D. E., Ripoll, C., Thiele, M., Fortune, B. E., Simonetto, D. A., Garcia-Tsao, G., & Bosch, J. (2024) · Hepatology · doi:10.1097/hep.0000000000000647 · Cited by 486
Hepatocellular Carcinoma: Current Management and Perspectives for the Future
Rahbari, N. N., Mehrabi, A., Mollberg, N. M., Müller, S. A., Koch, M., Büchler, M. W., & Weitz, J. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31820d944f · Cited by 453
Targeted Therapies for Hepatocellular Carcinoma
Villanueva, A., & Llovet, J. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.03.006 · Cited by 449
Thomas, M. B., Jaffe, D., Choti, M. M., Belghiti, J., Curley, S., Fong, Y., Gores, G., Kerlan, R., Merle, P., O'Neil, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.7805 · Cited by 394
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
Grothey, A., & Galanis, E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.110 · Cited by 356
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies
O'Connor, J. P. B., Jackson, A., Parker, G. J. M., Roberts, C., & Jayson, G. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.2 · Cited by 348
Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy
Kim, D. W., Talati, C., & Kim, R. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.07 · Cited by 333
Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Dimri, M., & Satyanarayana, A. (2020) · Cancers · doi:10.3390/cancers12020491 · Cited by 311
Isenberg, J. S., Martin-Manso, G., Maxhimer, J. B., & Roberts, D. D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2561 · Cited by 305
Dysregulation of apoptosis in hepatocellular carcinoma cells
Fabregat, I. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.513 · Cited by 280
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy
Zhao, Y., Zhang, Y.-N., Wang, K.-T., & Chen, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188391 · Cited by 278
Angiogenesis in chronic liver disease and its complications: Angiogenesis in CLD
Coulon, S., Heindryckx, F., Geerts, A., Van Steenkiste, C., Colle, I., & Van Vlierberghe, H. (2011) · Liver International · doi:10.1111/j.1478-3231.2010.02369.x · Cited by 276
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Abrams, T. A., Alberts, S. R., Anaya, D. A., Anders, R., Are, C., Brown, D., Chang, D. T., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0019 · Cited by 269
Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
Villanueva, A., Minguez, B., Forner, A., Reig, M., & Llovet, J. M. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080608.100623 · Cited by 254
Mazzocca, A., Fransvea, E., Lavezzari, G., Antonaci, S., & Giannelli, G. (2009) · Hepatology · doi:10.1002/hep.23118 · Cited by 127
Metadata
- Authors
- Siegel, A. B., Cohen, E. I., Ocean, A., Lehrer, D., Goldenberg, A., Knox, J. J., Chen, H., Clark-Garvey, S., Weinberg, A., Mandeli, J., Christos, P., Mazumdar, M., Popa, E., Brown, R. S., Rafii, S., & Schwartz, J. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-06-20
- Volume
- 26
- Issue
- 18
- Pages
- 2992-2998
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2136977965
- Cited by
- 506
- References
- 18
- FWCI
- 34.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.